MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000375" target="_blank" >RIV/00209805:_____/12:#0000375 - isvavai.cz</a>
Result on the web
<a href="http://www.diagnosticpathology.org/content/7/1/31" target="_blank" >http://www.diagnosticpathology.org/content/7/1/31</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1746-1596-7-31" target="_blank" >10.1186/1746-1596-7-31</a>

Result language
angličtina
Original language name
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
Original language description
Background: Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higherincidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients. Methods: Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological features of TNBC patients. Results: Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NS10357" target="_blank" >NS10357: Epidemiological, genetic, histological and clinical aspects of "triple-negative" (ER-alfa, PR, c-ErB2 negative) breast cancer in population of Czech women.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)